Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YFD
|
|||
| Former ID |
DIB009631
|
|||
| Drug Name |
PF-05212372
|
|||
| Synonyms |
PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth
Click to Show/Hide
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 1 | [1] | |
| Company |
Wyeth
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phospholipase A2 (PLA2G1B) | Target Info | Inhibitor | [2] |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Ether lipid metabolism | ||||
| Arachidonic acid metabolism | ||||
| Linoleic acid metabolism | ||||
| alpha-Linolenic acid metabolism | ||||
| Metabolic pathways | ||||
| Ras signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| Reactome | Acyl chain remodelling of PC | |||
| Acyl chain remodelling of PE | ||||
| Acyl chain remodelling of PI | ||||
| WikiPathways | Glycerophospholipid biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01415102) A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.. U.S. NationalInstitutes of Health. | |||
| REF 2 | Phagedena due to leishmaniasis. Immunologic and experimental studies. Ann Dermatol Syphiligr (Paris). 1976;103(1):23-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.